Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for elective hysterectomy at Mayo Clinic in Arizona~* ASA I, II, or III~Exclusion Criteria:~* Pregnancy~* Concomitant bowel surgery other than appendectomy~* Hypersensitivity to study drug or rescue medication~* Preoperative score for nausea greater than 4 out of 10 points~* Severe hepatic insufficiency (Child-Pugh score \> 9)~* Any condition which impairs the patient's ability to complete study assessments~* Intraoperative hemodynamic instability~* ICU admission~* Prolonged postoperative intubation~* Rifampin, carbamazepine, phenytoin, or other drugs which strongly induce CYP3A4 activity~* Other antiemetic within 12 hours prior to surgery~* Participation in a clinical trial using an investigational product

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant (Type: EXPERIMENTAL): 40 mg aprepitant
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).